Cenegermin

Drug Profile

Cenegermin

Alternative Names: Nerve growth factor - Anabasis/Dompe; Oxervate; rhNGF; Sentinel

Latest Information Update: 02 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Anabasis Pharma
  • Developer Dompe Farmaceutici; Ospedale San Raffaele
  • Class Eye disorder therapies; Nerve growth factors; Neuroprotectants; Proteins
  • Mechanism of Action Nerve growth factor receptor agonists; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Keratitis; Retinitis pigmentosa
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Keratitis
  • Phase II Dry eyes; Retinitis pigmentosa
  • Phase I Glaucoma

Most Recent Events

  • 20 Jul 2017 Preregistration for Keratitis in USA (Ophthalmic)
  • 20 Jul 2017 Registered for Keratitis in Liechtenstein, Norway, Iceland (Ophthalmic)
  • 20 Jul 2017 Registered for Keratitis in European Union (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top